Viron Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Viron Therapeutics - overview
Established
1997
Location
London, ON, Canada
Primary Industry
Biotechnology
About
Viron Therapeutics is a biotechnology firm focused on developing innovative therapies for secretory disorders, leveraging its proprietary porosome platform to address conditions such as Alzheimer's disease and cystic fibrosis. Founded in 1997 and headquartered in London, Canada, Viron Therapeutics specializes in innovative therapeutic solutions. The company has undergone pivotal developments in its strategy since inception, focusing solely on its proprietary porosome platform. In May 2006, Viron raised USD 20.
00 mn in a Series A funding round, led by Canadian Medical Discoveries Fund Inc. , with participation from Amgen Ventures, BDC Capital, GrowthWorks Capital, Novartis International AG, and Trudell Medical International. The company has completed 1 deal. No subsidiaries or parent companies are mentioned.
Viron Therapeutics develops innovative therapies utilizing its proprietary porosome platform designed to address secretory disorders related to diseases such as Alzheimer's, cystic fibrosis, and type 1 diabetes. The therapies integrate functional porosome machinery into target cells to enhance their secretory capabilities, aiming to improve patient outcomes by rectifying insulin and mucin secretion deficiencies and mitigating neurodegenerative processes. Viron Therapeutics generates revenue through partnerships and collaborations with healthcare providers, research institutions, and biotechnology companies. Their revenue model involves agreements for research and development, licensing, and commercialization of therapeutic products, emphasizing long-term contracts and clinical partnerships.
Specific pricing details for their flagship products are undisclosed, yet the approach aligns with the advanced nature of their therapies. Viron Therapeutics aims to use the proceeds from the USD 20. 00 mn Series A financing acquired in May 2006 to further develop its porosome technology and advance product offerings. The company plans to introduce new therapies targeting secretory disorders and expand its reach into North American and European markets by 2025.
Recent funding will support these initiatives, providing necessary resources for research and development efforts.
Current Investors
BDC Capital, GrowthWorks Capital, Amgen Ventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.vironinc.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Viron Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.